Britain’s National Institute for Health and Care Excellence (NICE) has struck yet another blow against costly cancer drugs. Saxagliptin could rival Merck’s newest diabetes drug, Januvia. And their vote underscored a growing feeling in the development community that the odds for the regulatory game are stacked against new diabetes drugs. Next year’s list could include several diabetes products approved this year. Despite offsetting growth from newer meds such as the melanoma therapy Yervoy and the anticoagulant it sells in partnership with Pfizer ($PFE), Eliquis, that same diabetes sale took its toll on Bristol-Myers’ top line in 2014, pushing sales down to $15.88 billion from $16.4 billion in 2013. The closing of the transaction as it relates to China remains subject to the satisfaction of certain conditions in the Sino-American Shanghai Squibb Pharmaceutical Company joint venture agreement between Bristol-Myers Squibb China and its joint venture partners. The Bristol-Myers Squibb Foundation has awarded an $85,000 grant to fund the year-long project and AmeriCares plans to donate approximately $500,000 worth of diabetes medicines and supplies over the next year to ensure patients receive proper treatment.
There was no significant difference in the risk of stent thrombosis between those treated with a DES or a BMS (HR 0.33, 95% CI 0.09-1.13; P=.08). The long-term results of this observational study are consistent with prior RCTs after adjusting for confounding variables. The number of lesions treated with DES to prevent one restenosis ranged from 11 to 47 in various subgroups.